Sacituzumab govitecan trials for Triple Negative Breast Cancer

All Sacituzumab govitecan trials · All Triple Negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Sacituzumab govitecan for Triple Negative Breast Cancer

• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
  NCT04434040 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
  NCT06081244 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 43 locations
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
  NCT04468061 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Sacituzumab Govitecan In TNBC
  NCT04230109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
  NCT06238921 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Sacituzumab govitecan for Triple Negative Breast Cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.